Thanks to new innovations in medical cannabis, smoking - and even vaping - for medical patients might soon be passé.

On July 5, Insys Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Syndros, a liquid form of the cannabinoid dronabinol - a lab-produced version of THC. 

"We believe that Syndros will be an important new treatment option for patients suffering from the devastating effects of chemotherapy induced nausea and vomiting, as well as those fighting anorexia associated with weight loss in AIDS,” said the company’s chairman, CEO and president, Dr. John N. Kapoor, in a release. The liquid preparation is currently awaiting scheduling by the U.S. Drug Enforcement Administration, and is expected to hit the market in the second half of 2016.

While Dronabinol has existed for decades, the drug isn't without its issues: in fact, as Popular Science reports it's "generally regarded as less effective for a number of reasons, not the least of which is that it lacks other compounds from natural marijuana that, when mixed with THC, create the effects everyone seems to be willing to break the law to get." 

According to Insys Therapeutics, however, the new formulation has "distinct advantages over the current formulation of dronabinol in soft gel capsule" - and according to other estimates, Syndros "has the potential to more than double" the company’s current $100 million a quarter revenue on its initial convertible market. 

Banner image: a katz / Shutterstock.com